StockData
Precigen, Inc. logo

Precigen, Inc. (PGEN) stock analysis

PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30256% above fair value
$4.66−0.06 (-1.27%)

Close on Nov 12, 2026Market cap $1.67BP/E 116.5Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth0Performance4Health2Dividend0

Weak6 of 30 checks passed

Precigen passes 6 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
0/6
Past performance
4/6
Financial health
2/6
Dividend
0/6

What stands out

  • Return on capital over 10%

    Return on invested capital was 147%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Precigen's return on equity of 38.8% is above the Drugs median of -58.9%.

  • Net margin above its 5-year average

    Net margin was 15.6% over the last twelve months, against a 5-year average of -1577%.

  • Net margin above the industry

    Precigen's net margin of 15.6% is above the Drugs median of -53.0%.

What to watch

  • Margin of safety under 20%

    The price is 256% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $4.72 is above our fair value estimate of $1.33.

  • Return on equity under 15%

    Return on equity was 38.8% over the last twelve months and averaged -233% over five years; we look for 15% on both.

  • High debt

    Debt is 112% of shareholders' equity, above the 40% we consider low.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E above the industry

    Precigen's P/E of 118.0 is above the Drugs median of 25.1.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Precigen's price-to-book of 20.17 is above the Drugs median of 2.29.

  • Trading above fair value

    The share price of $4.72 is above our fair value estimate of $1.33.

  • Margin of safety under 20%

    The price is 256% above fair value, so there is no margin of safety.

Growth0/6

  • Revenue growing under 10% a year

    Revenue grew -28.9% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growth against the industry

    Needs revenue for this year and last.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance4/6

  • Return on equity under 15%

    Return on equity was 38.8% over the last twelve months and averaged -233% over five years; we look for 15% on both.

  • Return on capital over 10%

    Return on invested capital was 147%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Precigen's return on equity of 38.8% is above the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 15.6% over the last twelve months, against a 5-year average of -1577%.

  • Net margin above the industry

    Precigen's net margin of 15.6% is above the Drugs median of -53.0%.

Financial health2/6

  • High debt

    Debt is 112% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 256% five years ago to 112%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -77.7% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense 2.8 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 5.58 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -5.17; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Precigen has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$1.33

The share price is 256% above this estimate.

20%+ below
Near fair value
20%+ above
$4.72Price$1.33Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E25.1×–25.1×$1.0053%
EV/EBITDA17.1×–17.1×$1.7047%
Fair value$1.33100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$40.84M
Value traded per 1% price move
$10.55M

Downside

High risk

Typical loss in a bad month
36.0%
Volatility (annualized)
85%
Sharpe ratio, 1 year
0.16
Beta to the S&P 500 (5Y)
1.64

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

–

Operating margin

-1141.1%

Net margin

-2588.2%−2055.2 pts over 5 years

See a number that looks wrong?